Adrian is a seasoned IP lawyer who relishes immersing himself in his client’s technology, product roadmap and patent/IP strategy. He is regularly involved in the negotiation and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.

Adrian has a wealth of experience in handling the IP aspects of University spin-outs, IPOs and other major corporate transactions and disputes, including for FTSE 100 and Fortune 500 corporations. He is also a valued patent litigator, having recently advised on disputes involving pharmaceuticals, somatic cell therapy, semiconductor chip design, inkjet printing technology, digital compression algorithms, LCD flat-panel technology, telecoms and pharmaceuticals. He also frequently helps clients with disputes involving confidential information, database rights, trade marks, copyright and designs.

Adrian publishes and speaks regularly on a variety of intellectual property issues.

CV ansehen CV ausblenden

Aktuelle News & Insights

Gesellschaftsrecht/ M&A & Kapitalmärkte

Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58 million

14. Juli 2022

von mehreren Autoren

Klicken Sie hier für Details
UPC

Seven steps to UPC readiness

6. Mai 2022
Briefing

von mehreren Autoren

Klicken Sie hier für Details
Gesellschaftsrecht/ M&A & Kapitalmärkte

Advising New Science Ventures as lead investor on Paragraf's $60 million Series B funding round

4. März 2022

von Ross McNaughton und Adrian Toutoungi

Klicken Sie hier für Details
Gesellschaftsrecht/ M&A & Kapitalmärkte

Advising Placid0 on its acquisition by eyecare brand WALDO

25. Februar 2022

von mehreren Autoren

Klicken Sie hier für Details

Meet me at

22. September

09:30 - 18:00

London
Branchenevent

Pharma forum 2022

A day exploring the legal and commercial issues that matter most to pharmaceutical and biologics companies

Mehr